Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -44% Improvement Relative Risk ICU admission -5% Hospitalization time -5% no CI Mortality (b) -117% levels ICU admission (b) 65% levels Progression 79% levels c19early.org/d Cannata-Andía et al. NCT04552951 COVID-VIT-D Vitamin D RCT LATE Is late treatment with vitamin D beneficial for COVID-19? RCT 543 patients in multiple countries Higher mortality with vitamin D (not stat. sig., p=0.31) Cannata-Andía et al., BMC Medicine, doi:10.1186/s12916-022-02290-8 Favors vitamin D Favors control
A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D — a randomised multicentre international clinical trial
Cannata-Andía et al., BMC Medicine, doi:10.1186/s12916-022-02290-8, COVID-VIT-D, NCT04552951 (history)
Cannata-Andía et al., A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the.., BMC Medicine, doi:10.1186/s12916-022-02290-8, COVID-VIT-D, NCT04552951
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 274 very late stage (>80% pulmonary involvement at baseline) hospitalized COVID-19 patients treated with a single dose of cholecalciferol, and 269 control patients, showing no significant differences. High serum calcidiol levels at admission were associated with lower pulmonary involvement, shorter hospitalization, and lower ICU admission.
Serum levels increased in the treatment group, however average levels were still insufficient at discharge. Calcifediol or calcitriol, which avoids several days delay in conversion, may be more successful, especially with this very late stage usage.
100,000IU cholecalciferol. This study is excluded in the after exclusion results of meta analysis: very late stage study using cholecalciferol instead of calcifediol or calcitriol.
risk of death, 44.0% higher, RR 1.44, p = 0.31, treatment 22 of 274 (8.0%), control 15 of 269 (5.6%).
risk of ICU admission, 4.9% higher, RR 1.05, p = 0.82, treatment 47 of 274 (17.2%), control 44 of 269 (16.4%).
hospitalization time, 5.3% higher, relative time 1.05, treatment 274, control 269.
risk of death, 117.0% higher, RR 2.17, p = 0.20, high D levels 87, low D levels 96, >25 vs. ≤10 ng/mL, adjusted by demographics, comorbidities, and laboratory parameters, outcome based on serum levels.
risk of ICU admission, 65.0% lower, RR 0.35, p = 0.04, high D levels 87, low D levels 96, >25 vs. ≤10 ng/mL, adjusted by demographics, comorbidities, and laboratory parameters, outcome based on serum levels.
risk of progression, 79.0% lower, RR 0.21, p = 0.003, high D levels 87, low D levels 96, pulmonary involvment at admission, >25 vs. ≤10 ng/mL, adjusted by demographics, comorbidities, and laboratory parameters, outcome based on serum levels.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cannata-Andía et al., 18 Feb 2022, Randomized Controlled Trial, multiple countries, peer-reviewed, median age 59.0, 22 authors, dosage 100,000IU single dose, trial NCT04552951 (history) (COVID-VIT-D).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: (2022) 20:83 Cannata‑Andía et al. BMC Medicine https://doi.org/10.1186/s12916-022-02290-8 RESEARCH ARTICLE Open Access A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial Jorge B. Cannata‑Andía1,2,3,4*† , Augusto Díaz‑Sottolano2,5†, Pehuén Fernández6,7,8†, Carmen Palomo‑Antequera1,2,3, Pablo Herrero‑Puente1,2,3, Ricardo Mouzo9, Natalia Carrillo‑López1,2,4, Sara Panizo1,2,4, Guillermo H. Ibañez10, Carlos A. Cusumano11, Carolina Ballarino12, Vicente Sánchez‑Polo13, Jacqueline Pefaur‑Penna14,15, Irene Maderuelo‑Riesco16, Jesús Calviño‑Varela17, Mónica D. Gómez18, Carlos Gómez‑Alonso1,2,3,4, John Cunningham19, Manuel Naves‑Díaz1,2,4*†, Walter Douthat6,7,8†, José L. Fernández‑Martín1,2,4† and the COVID-VIT-D trial collaborators Abstract Background: Vitamin D status has been implicated in COVID-19 disease. The objective of the COVID-VIT-D trial was to investigate if an oral bolus of cholecalciferol (100,000 IU) administered at hospital admission influences the out‑ comes of moderate-severe COVID-19 disease. In the same cohort, the association between baseline serum calcidiol levels with the same outcomes was also analysed. Methods: The COVID-VIT-D is a multicentre, international, randomised, open label, clinical trial conducted through‑ out 1 year. Patients older than 18 years with moderate-severe COVID-19 disease requiring hospitalisation were included. At admission, patients were randomised 1:1 to receive a single oral bolus of cholecalciferol (n=274) or noth‑ ing (n=269). Patients were followed from admission to discharge or death. Length of hospitalisation, admission to intensive care unit (ICU) and mortality were assessed. Results: In the randomised trial, comorbidities, biomarkers, symptoms and drugs used did not differ between groups. Median serum calcidiol in the cholecalciferol and control groups were 17.0 vs. 16.1 ng/mL at admission and 29.0 vs. 16.4 ng/mL at discharge, respectively. The median length of hospitalisation (10.0 [95%CI 9.0–10.5] vs. 9.5 *Correspondence: cannata@hca.es; jorge.cannata@gmail.com; mnaves. huca@gmail.com † Augusto Díaz-Sottolano and Pehuén Fernández are second authors. † Walter Douthat and José L. Fernández-Martín are senior authors (two last authors). † Jorge B. Cannata-Andía and Manuel Naves-Díaz contributed equally to this work as corresponding authors. 1 Hospital Universitario Central de Asturias (HUCA), Avda. Roma s/n., 33011 Oviedo, Spain Full list of author information is available at the end of the article © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit